Scientific Library of Tomsk State University

   E-catalog        

Normal view MARC view

Drug Treatment of Sleep Disorders electronic resource edited by Antonio Guglietta.

Contributor(s): Guglietta, Antonio [editor.] | SpringerLink (Online service)Material type: TextTextSeries: Milestones in Drug TherapyPublication details: Cham : Springer International Publishing : Imprint: Springer, 2015Description: VIII, 297 p. 23 illus., 14 illus. in color. online resourceContent type: text Media type: computer Carrier type: online resourceISBN: 9783319115146Subject(s): medicine | Neurosciences | pharmacology | Psychopharmacology | Pharmacotherapy | Biomedicine | Pharmacology/Toxicology | Neurosciences | Pharmacotherapy | PsychopharmacologyDDC classification: 615 LOC classification: RM1-950Online resources: Click here to access online
Contents:
An overview of sleep physiology and sleep regulation -- Neuronal networks regulating sleep and arousal: effect of drugs -- Classification of sleep disorders -- Development of new therapeutical agents for treatment of insomnia and other sleep disorders -- Low dose doxepin for insomnia -- Lorediplon: a new GABAa modulator drug for treatment of insomnia -- Zolpidem sublingual formulations -- Eszopiclone: review and clinical applications in chronic and co-morbid insomnia -- Orexin/hypocretin antagonists in insomnia: from bench to clinic -- Modafinil and armodafinil -- Sodium oxybate (Xyrem®): a new and effective treatment for narcolepsy with cataplexy -- Cell therapy to treat narcolepsy -- Tasimelteon -- The past, present and future of drug development and treatment in sleep disorders.
In: Springer eBooksSummary: Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.
Tags from this library: No tags from this library for this title. Log in to add tags.
No physical items for this record

An overview of sleep physiology and sleep regulation -- Neuronal networks regulating sleep and arousal: effect of drugs -- Classification of sleep disorders -- Development of new therapeutical agents for treatment of insomnia and other sleep disorders -- Low dose doxepin for insomnia -- Lorediplon: a new GABAa modulator drug for treatment of insomnia -- Zolpidem sublingual formulations -- Eszopiclone: review and clinical applications in chronic and co-morbid insomnia -- Orexin/hypocretin antagonists in insomnia: from bench to clinic -- Modafinil and armodafinil -- Sodium oxybate (Xyrem®): a new and effective treatment for narcolepsy with cataplexy -- Cell therapy to treat narcolepsy -- Tasimelteon -- The past, present and future of drug development and treatment in sleep disorders.

Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.

There are no comments on this title.

to post a comment.